What is the natural course of submandibular salivary gland cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Natural Course of Submandibular Salivary Gland Cancer

Submandibular gland cancer follows an aggressive natural course with high rates of locoregional progression, distant metastasis, and mortality, with approximately 80% of patients dying from their disease if left untreated or inadequately treated. 1

Disease Progression Pattern

The natural history is characterized by progressive local invasion with eventual locoregional and distant spread:

  • Tumor size and clinical stage are the most critical determinants of disease progression and survival. 2
  • Local extension manifests as facial paralysis, trismus, and cutaneous infiltration as the tumor invades adjacent structures. 2
  • Regional lymph node metastases occur in approximately 16-20% of patients at presentation, with an occult metastasis rate of 4%. 3, 4
  • Distant metastases are present in 7% of patients at diagnosis, with distant-only recurrence occurring in 28% of cases. 3, 4

Histologic Patterns and Their Impact

The submandibular gland has a higher proportion of malignant tumors compared to the parotid gland, making these tumors inherently more dangerous:

  • Adenoid cystic carcinoma is the most common histology (41-56% of cases), followed by adenocarcinoma (15%), mucoepidermoid carcinoma (15%), and malignant mixed tumors (11%). 3, 4, 5
  • High-grade histology and adenoid cystic carcinoma independently predict worse disease-free survival. 6
  • Perineural invasion, present in a significant proportion of cases, is an independent predictor of shorter disease-free survival. 6

Survival and Recurrence Without Treatment

The untreated natural course results in poor outcomes:

  • Five-year cause-specific survival is 60% and 10-year survival is 48% even with treatment, suggesting dismal outcomes without intervention. 3
  • Disease recurrence occurs in 44% of treated patients, with locoregional control at 5 years being only 30% with surgery alone. 3, 4
  • Five-year disease-free survival is 63-68% with treatment, indicating that untreated disease would have substantially worse outcomes. 4, 5
  • The 15-year survival for submandibular gland malignancies is only 21-47%, reflecting the aggressive biology of these tumors. 1

Clinical Presentation During Natural Progression

As the disease progresses untreated, patients develop:

  • Progressive enlargement of the submandibular mass with locoregional extension. 2
  • Signs of malignancy including facial nerve paralysis, trismus, and skin infiltration. 2
  • Cervical lymphadenopathy as regional metastases develop. 2
  • Systemic symptoms from distant metastases, particularly to lungs and bones. 3

Important Clinical Caveat

Only 12% of patients (3 out of 25) show clinical signs of probable malignancy at presentation, making early detection challenging and emphasizing the insidious nature of disease progression. 4 This underscores why submandibular masses require prompt surgical evaluation rather than observation, as the natural course involves silent progression until advanced stages.

References

Research

Tumors of the major and minor salivary glands.

CA: a cancer journal for clinicians, 1984

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Malignant submandibular gland tumors. A review of 91 patients.

American journal of clinical oncology, 1988

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.